MarketCap
Facebook
X
Telegram
Assertio Holdings Net Debt | ASRT
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Assertio Holdings
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 29.1 M | -11.4 M | -34 M | 1.86 M | 26.5 M | 63.3 M | 316 M | 455 M | 500 M | 601 M | 705 M | -259 M | -245 M | -29.1 M | -24 M |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 705 M | -259 M | 140 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Drug manufacturers industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Agile Therapeutics
AGRX
|
-676 K | - | 10.11 % | $ 58.2 M |  USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-49.7 M | - | - | $ 2.06 B |  France |
 |
Organogenesis Holdings
ORGO
|
-75.9 M | $ 0.84 | 0.19 % | $ 106 M | USA |
 |
Evoke Pharma
EVOK
|
-13.4 M | - | - | $ 36.6 M | USA |
 |
Pacira BioSciences
PCRX
|
223 M | $ 36.43 | 0.03 % | $ 1.62 B | USA |
 |
Perrigo Company plc
PRGO
|
3.1 B | $ 15.83 | 0.83 % | $ 2.19 B | USA |
 |
Rockwell Medical
RMTI
|
-730 K | $ 7.76 | 2.04 % | $ 279 M | USA |
 |
Solid Biosciences
SLDB
|
-38.7 M | $ 6.65 | 7.52 % | $ 582 M | USA |
 |
Sundial Growers
SNDL
|
-82.3 M | $ 1.42 | 2.54 % | $ 366 M |  Canada |
 |
Tilray
TLRY
|
-98 M | $ 2.91 | 3.56 % | $ 325 M | Canada |
 |
Aerie Pharmaceuticals
AERI
|
-11.1 M | - | - | $ 754 M | USA |
 |
Alimera Sciences
ALIM
|
-11.2 M | - | - | $ 142 M | USA |
 |
Veru
VERU
|
-12.7 M | $ 2.14 | 3.88 % | $ 31.3 M | USA |
 |
Viatris
VTRS
|
11.3 B | $ 19.72 | 5.03 % | $ 22.9 B | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-22.5 M | - | 0.86 % | $ 117 M | USA |
 |
cbdMD
YCBD
|
-521 K | $ 0.42 | 6.96 % | $ 1.69 M | USA |
 |
China Pharma Holdings
CPHI
|
-162 K | $ 0.57 | 8.66 % | $ 2.45 M |  China |
 |
Lannett Company
LCI
|
529 M | - | 1.15 % | $ 7.11 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-50.3 M | - | - | $ 55.5 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
2.43 M | - | -39.89 % | $ 27.7 M | USA |
 |
PetIQ
PETQ
|
329 M | - | 1.64 % | $ 400 M | USA |
 |
Tricida
TCDA
|
-7.08 M | - | - | $ 3.25 M | USA |
 |
DURECT Corporation
DRRX
|
-8.8 M | - | - | $ 50.1 M | USA |
 |
Athenex
ATNX
|
-28.3 M | - | -23.39 % | $ 1.76 M | USA |
 |
PLx Pharma
PLXP
|
-21.8 M | - | -27.8 % | $ 2.56 M | USA |
 |
Catalent
CTLT
|
4.58 B | - | - | $ 11.5 B | USA |
 |
Endo International plc
ENDP
|
7.37 B | - | - | $ 28.9 M |  Irlanda |
 |
OptiNose
OPTN
|
-82 M | - | - | $ 1.08 B | USA |
 |
Radius Health
RDUS
|
-111 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
-6.65 M | - | -4.76 % | $ 65.3 M | USA |
 |
Canopy Growth Corporation
CGC
|
-139 M | $ 0.65 | -3.6 % | $ 194 M | Canada |
 |
Aurora Cannabis
ACB
|
-95 M | $ 5.24 | 0.87 % | $ 287 M | Canada |
 |
Harrow Health
HROW
|
178 M | $ 26.86 | 3.15 % | $ 987 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
-6.5 M | $ 5.26 | 4.99 % | $ 78.1 M | USA |
 |
Relmada Therapeutics
RLMD
|
-2.5 M | $ 3.92 | 3.98 % | $ 155 M | USA |
 |
Emergent BioSolutions
EBS
|
369 M | $ 6.04 | 3.25 % | $ 323 M | USA |
 |
Cronos Group
CRON
|
-790 M | $ 3.62 | -2.82 % | $ 1.39 B | Canada |
 |
Evolus
EOLS
|
94.8 M | $ 6.86 | 0.88 % | $ 442 M | USA |
 |
Bausch Health Companies
BHC
|
19.3 B | $ 8.19 | 2.7 % | $ 3.04 B | Canada |
 |
OrganiGram Holdings
OGI
|
-102 M | $ 0.88 | -5.39 % | $ 83.9 M | Canada |
 |
SCYNEXIS
SCYX
|
-19.1 M | $ 3.51 | 6.21 % | $ 175 M | USA |
 |
HEXO Corp.
HEXO
|
-80.4 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-934 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
Sonoma Pharmaceuticals
SNOA
|
-1.78 M | $ 1.12 | 5.1 % | $ 1.89 M | USA |
 |
TherapeuticsMD
TXMD
|
-1.39 M | $ 1.7 | -0.58 % | $ 19.7 M | USA |
 |
AcelRx Pharmaceuticals
ACRX
|
-6.59 M | - | 7.5 % | $ 6.35 M | USA |
 |
Jupiter Wellness
JUPW
|
-21.7 K | - | - | $ 33.6 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-101 M | - | - | $ 193 M | Canada |
 |
ProPhase Labs
PRPH
|
549 K | - | - | $ 5.07 M | USA |